Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
Globe Newswire•07/10/2026•08:45 ET
0
Key Highlights
- ➤Moleculin (MBRX) to present oncology pipeline at 2026 Maxim Growth Summit
- ➤MIRACLE Part A enrollment completed in Phase 2/3 AnnAraC trial
- ➤Comprehensive MIRACLE Part A data readout remains planned for Q1 2027
- ➤Moleculin requires significant additional financing to conduct planned clinical trials
Expert Statements
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
“Mr. Klemp will discuss Moleculin’s oncology pipeline and recent clinical progress, including the Company’s lead investigational candidate, Annamycin, and its ongoing Phase 2/3 MIRACLE clinical trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML).”
HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of the presentation are as follows:
Session: Advances in Oncology Panel Presenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin Date/time: Wednesday, October 14, 2026, from 9:00 - 10:00 a.m. ET Location: NYY Room at the Hard Rock Hotel NYC
Get started
Create a free account to read the full story.